Market Chatter: Johnson & Johnson in Talks to Acquire Protagonist Therapeutics-March 2024-www.financetom.com

Market Chatter: Johnson & Johnson in Talks to Acquire Protagonist Therapeutics

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Market Chatter: Johnson & Johnson in Talks to Acquire Protagonist Therapeutics

Oct 10, 2025 8:42 AM

11:28 AM EDT, 10/10/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) is in talks to acquire Protagonist Therapeutics ( PTGX ) , The Wall Street Journal reported Friday, citing people familiar with the matter.

Johnson & Johnson ( JNJ ) and Protagonist did not immediately reply to requests for comment from MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 191.72, Change: +0.63, Percent Change: +0.33

Previous page： BRIEF-Blank Check Company Pan-Africa Corporation Files For IPO Of Up To $125 Million - SEC Filing Next page： Affinity Bancshares' Q3 profit rises on interest income growth

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

BRIEF-Blank Check Company Pan-Africa Corporation Files For IPO Of Up To $125 Million - SEC Filing

Oct 24, 2025

Oct 24 (Reuters) - Pan-Africa Corporation: * BLANK CHECK CO PAN-AFRICA CORPORATION FILES FOR IPO OF UP TO $125 MILLION - SEC FILING * PAN-AFRICA CORP: INTEND TO APPLY TO HAVE UNITS LISTED ON NASDAQ UNDER SYMBOL BLEUU - SEC FILING * PAN-AFRICA CORP - SANTANDER IS UNDERWRITER TO IPO Source text: ...

Affinity Bancshares' Q3 profit rises on interest income growth

Oct 24, 2025

Overview * Affinity Bancshares ( AFBI ) Q3 net income rises to $2.2 mln from $1.7 mln year-over-year * Company's Q3 net interest income increases to $7.8 mln from $7.4 mln year-over-year * Net interest margin for Q3 decreases to 3.49% from 3.52% year-over-year Outlook * Company did not provide specific guidance for future quarters or full year in press...

General Motors Insider Sold Shares Worth $17,316,834, According to a Recent SEC Filing

Oct 24, 2025

04:40 PM EDT, 10/24/2025 (MT Newswires) -- Mark L Reuss, President, on October 22, 2025, sold 260,600 shares in General Motors ( GM ) for $17,316,834. Following the Form 4 filing with the SEC, Reuss has control over a total of 98,006 common shares of the company, with 98,006 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1467858/000149236225000005/xslF345X05/wk-form4_1761337840.xml ...

Arvinas' ARV-806 Shows Preclinical Tumor Inhibition in KRAS G12D Cancer Models

Oct 24, 2025

04:44 PM EDT, 10/24/2025 (MT Newswires) -- Arvinas ( ARVN ) said Friday its KRAS G12D degrader candidate, ARV-806, demonstrated robust and durable tumor inhibition and potent target degradation in preclinical models of pancreatic, colorectal, and lung cancers. The company said ARV-806 achieved picomolar potency in degrading KRAS G12D and showed more than 25-fold stronger antiproliferative activity than other G12D-targeting...